Ranolazine composition and preparation method thereof
Belonging to the field of pharmaceutical preparations, the invention relates to a ranolazine composition and a preparation method thereof. The composition comprises ranolazine, direct pressure type silicified microcrystalline cellulose, sodium alginate or/and sodium carboxymethyl cellulose, and one...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HUANG QIBIAO |
| description | Belonging to the field of pharmaceutical preparations, the invention relates to a ranolazine composition and a preparation method thereof. The composition comprises ranolazine, direct pressure type silicified microcrystalline cellulose, sodium alginate or/and sodium carboxymethyl cellulose, and one or more excipients, wherein the content of ranolazine in the prescription is 65%-85% (W/W), the content of the sodium alginate in the prescription is 2%-15% (W/W), the content of the sodium carboxymethyl cellulose in the prescription is 2%-15% (W/W), and the content of the direct pressure type silicified microcrystalline cellulose in the prescription is 3%-19% (W/W). The preparation process of the composition is a powder direct pressure process. The ranolazine sustained release tablet prepared by the method is low in cost and simple in process, and can greatly reduce the treatment cost of patients.
本发明涉及一种雷诺嗪组合物及其制备方法，属于药物制剂领域。所述组合物，包括雷诺嗪、直压型硅化微晶纤维素、海藻酸钠或/和羧甲基纤维素钠，以及一种或多种赋形剂，所述雷诺嗪在处方中含量为65％-85％(W/W)，所述海藻酸钠在处方中含量为2％ |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN111000818A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN111000818A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN111000818A3</originalsourceid><addsrcrecordid>eNrjZDANSszLz0msysxLVUjOzy3IL84syczPU0jMS1EoKEotSCxKBPNzU0sy8lMUSjJSi1Lz03gYWNMSc4pTeaE0N4Oim2uIs4duakF-fGpxQWJyal5qSbyzn6GhoYGBgYWhhaMxMWoArvItsQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Ranolazine composition and preparation method thereof</title><source>esp@cenet</source><creator>HUANG QIBIAO</creator><creatorcontrib>HUANG QIBIAO</creatorcontrib><description>Belonging to the field of pharmaceutical preparations, the invention relates to a ranolazine composition and a preparation method thereof. The composition comprises ranolazine, direct pressure type silicified microcrystalline cellulose, sodium alginate or/and sodium carboxymethyl cellulose, and one or more excipients, wherein the content of ranolazine in the prescription is 65%-85% (W/W), the content of the sodium alginate in the prescription is 2%-15% (W/W), the content of the sodium carboxymethyl cellulose in the prescription is 2%-15% (W/W), and the content of the direct pressure type silicified microcrystalline cellulose in the prescription is 3%-19% (W/W). The preparation process of the composition is a powder direct pressure process. The ranolazine sustained release tablet prepared by the method is low in cost and simple in process, and can greatly reduce the treatment cost of patients.
本发明涉及一种雷诺嗪组合物及其制备方法，属于药物制剂领域。所述组合物，包括雷诺嗪、直压型硅化微晶纤维素、海藻酸钠或/和羧甲基纤维素钠，以及一种或多种赋形剂，所述雷诺嗪在处方中含量为65％-85％(W/W)，所述海藻酸钠在处方中含量为2％</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200414&DB=EPODOC&CC=CN&NR=111000818A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200414&DB=EPODOC&CC=CN&NR=111000818A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HUANG QIBIAO</creatorcontrib><title>Ranolazine composition and preparation method thereof</title><description>Belonging to the field of pharmaceutical preparations, the invention relates to a ranolazine composition and a preparation method thereof. The composition comprises ranolazine, direct pressure type silicified microcrystalline cellulose, sodium alginate or/and sodium carboxymethyl cellulose, and one or more excipients, wherein the content of ranolazine in the prescription is 65%-85% (W/W), the content of the sodium alginate in the prescription is 2%-15% (W/W), the content of the sodium carboxymethyl cellulose in the prescription is 2%-15% (W/W), and the content of the direct pressure type silicified microcrystalline cellulose in the prescription is 3%-19% (W/W). The preparation process of the composition is a powder direct pressure process. The ranolazine sustained release tablet prepared by the method is low in cost and simple in process, and can greatly reduce the treatment cost of patients.
本发明涉及一种雷诺嗪组合物及其制备方法，属于药物制剂领域。所述组合物，包括雷诺嗪、直压型硅化微晶纤维素、海藻酸钠或/和羧甲基纤维素钠，以及一种或多种赋形剂，所述雷诺嗪在处方中含量为65％-85％(W/W)，所述海藻酸钠在处方中含量为2％</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDANSszLz0msysxLVUjOzy3IL84syczPU0jMS1EoKEotSCxKBPNzU0sy8lMUSjJSi1Lz03gYWNMSc4pTeaE0N4Oim2uIs4duakF-fGpxQWJyal5qSbyzn6GhoYGBgYWhhaMxMWoArvItsQ</recordid><startdate>20200414</startdate><enddate>20200414</enddate><creator>HUANG QIBIAO</creator><scope>EVB</scope></search><sort><creationdate>20200414</creationdate><title>Ranolazine composition and preparation method thereof</title><author>HUANG QIBIAO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN111000818A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HUANG QIBIAO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HUANG QIBIAO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Ranolazine composition and preparation method thereof</title><date>2020-04-14</date><risdate>2020</risdate><abstract>Belonging to the field of pharmaceutical preparations, the invention relates to a ranolazine composition and a preparation method thereof. The composition comprises ranolazine, direct pressure type silicified microcrystalline cellulose, sodium alginate or/and sodium carboxymethyl cellulose, and one or more excipients, wherein the content of ranolazine in the prescription is 65%-85% (W/W), the content of the sodium alginate in the prescription is 2%-15% (W/W), the content of the sodium carboxymethyl cellulose in the prescription is 2%-15% (W/W), and the content of the direct pressure type silicified microcrystalline cellulose in the prescription is 3%-19% (W/W). The preparation process of the composition is a powder direct pressure process. The ranolazine sustained release tablet prepared by the method is low in cost and simple in process, and can greatly reduce the treatment cost of patients.
本发明涉及一种雷诺嗪组合物及其制备方法，属于药物制剂领域。所述组合物，包括雷诺嗪、直压型硅化微晶纤维素、海藻酸钠或/和羧甲基纤维素钠，以及一种或多种赋形剂，所述雷诺嗪在处方中含量为65％-85％(W/W)，所述海藻酸钠在处方中含量为2％</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN111000818A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Ranolazine composition and preparation method thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A07%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HUANG%20QIBIAO&rft.date=2020-04-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN111000818A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |